Abacavir hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412420

CAS#: 136777-48-5 (HCl)

Description: Abacavir hydrochloride is the salt form of Abacavir (ABC), an antiretroviral medication used to prevent and treat HIV/AIDS. It is of the nucleoside analog reverse transcriptase inhibitor (NRTI) type. Viral strains that are resistant to zidovudine (AZT) or lamivudine (3TC) are generally, but not always, sensitive to abacavir. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. It is available under the trade name Ziagen and in the combination formulations abacavir/lamivudine/zidovudine, abacavir/dolutegravir/lamivudine, abacavir/lamivudine.


Chemical Structure

img
Abacavir hydrochloride
CAS# 136777-48-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 412420
Name: Abacavir hydrochloride
CAS#: 136777-48-5 (HCl)
Chemical Formula: C14H19ClN6O
Exact Mass:
Molecular Weight: 322.79
Elemental Analysis: C, 52.09; H, 5.93; Cl, 10.98; N, 26.04; O, 4.96

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 136470-78-5 (free base)   136777-48-5 (HCl)   168146-84-7 (succinate)   188062-50-2 (sulfate)   1446418-48-9 (hydroxyacetate)   384380-52-3 (caeboxylate)    

Synonym: Abacavir hydrochloride; UNII-RP0T719KX7

IUPAC/Chemical Name: ((1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol hydrochloride

InChi Key: QXNOPHSMRJNHHG-SCYNACPDSA-N

InChi Code: InChI=1S/C14H18N6O.ClH/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21;/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19);1H/t8-,10+;/m1./s1

SMILES Code: Nc(nc1NC2CC2)nc3c1ncn3[C@@H]4C[C@@H](C=C4)CO.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 322.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fantauzzi A, Floridia M, Falasca F, Spanedda P, Turriziani O, Vullo V, Mezzaroma I. Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization. New Microbiol. 2015 Oct 20;38(4). [Epub ahead of print] PubMed PMID: 26485011.

2: Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2015 Oct 5. pii: S1473-3099(15)00319-9. doi: 10.1016/S1473-3099(15)00319-9. [Epub ahead of print] PubMed PMID: 26481928.

3: Naisbitt DJ, Yang EL, Alhaidari M, Berry NG, Lawrenson AS, Farrell J, Martin P, Strebel K, Owen A, Pye M, French N, Clarke SE, O'Neill PM, Park BK. Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. AIDS. 2015 Sep 13. [Epub ahead of print] PubMed PMID: 26372480.

4: Wilson B, Paladugu L, Priyadarshini SR, Jenita JJ. Development of albumin-based nanoparticles for the delivery of abacavir. Int J Biol Macromol. 2015 Sep 10;81:763-767. doi: 10.1016/j.ijbiomac.2015.09.015. [Epub ahead of print] PubMed PMID: 26365020.

5: Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, Pappa K. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015 Sep 9. [Epub ahead of print] PubMed PMID: 26355674.

6: Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015 Aug 7. [Epub ahead of print] PubMed PMID: 26262777.

7: Gao S, Zhu S, Huang R, Lu Y, Zheng G. Efficient synthesis of the intermediate of abacavir and carbovir using a novel (+)-γ-lactamase as a catalyst. Bioorg Med Chem Lett. 2015 Sep 15;25(18):3878-81. doi: 10.1016/j.bmcl.2015.07.054. Epub 2015 Jul 26. PubMed PMID: 26235952.

8: Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med. 2015 Jul 14. doi: 10.1111/hiv.12281. [Epub ahead of print] PubMed PMID: 26176344.

9: Neumanova Z, Cerveny L, Greenwood SL, Ceckova M, Staud F. Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir. Reprod Toxicol. 2015 Nov;57:176-82. doi: 10.1016/j.reprotox.2015.07.070. Epub 2015 Jul 10. PubMed PMID: 26169552.

10: Young B, Squires KE, Tashima K, Henry K, Schneider S, LaMarca A, Zhao HH, Ross LL, Shaefer MS. Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2015 Aug;16(4):125-9. doi: 10.1179/1528433614Z.0000000017. Epub 2015 Jul 2. PubMed PMID: 26133089.